We are live on
!
Find out more
CCM
Cutter Capital Management Portfolio holdings
AUM
$230M
1-Year Est. Return
11.53%
This Fund
S&P 500
This Quarter
Est. Return
+14.41%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$209M
AUM Growth
–
Cap. Flow
+$186M
Cap. Flow
% of AUM
89.13%
Top 10 Holdings %
Top 10 Hldgs %
59.43%
Holding
23
New
23
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$15.6M |
| 2 |
Merck
MRK
|
+$14.1M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$11.5M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$10.8M |
| 5 |
Insmed
INSM
|
+$10.7M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$197B
| $16.5M | 7.9% |
+57,381
| New | +$15.6M |
|
|
2
Merck
MRK
$307B
| $14.8M | 7.09% |
+136,098
| New | +$14.1M |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $13.4M | 6.43% |
+947,418
| New | +$10.8M |
|
|
4
Insmed
INSM
$23.2B
| $12.8M | 6.13% |
+413,499
| New | +$10.7M |
|
|
5
BioMarin Pharmaceuticals
BMRN
$11.4B
| $12.5M | 5.99% |
+129,906
| New | +$11.5M |
|
6
Roivant Sciences
ROIV
$24.5B
| $11.2M | 5.37% |
+1,000,000
| New | +$9.75M |
|
7
Exelixis
EXEL
$14B
| $11.1M | 5.3% |
+462,305
| New | +$10.1M |
|
8
Teva Pharmaceuticals
TEVA
$36.1B
| $11.1M | 5.3% |
+1,061,668
| New | +$9.91M |
|
9
Royalty Pharma
RPRX
$25.4B
| $10.4M | 4.97% |
+370,000
| New | +$10.2M |
|
10
Acadia Pharmaceuticals
ACAD
$4.3B
| $10.4M | 4.95% |
+330,973
| New | +$7.9M |
|
11
BioCryst Pharmaceuticals
BCRX
$2.32B
| $9.12M | 4.36% |
+1,521,812
| New | +$8.82M |
|
12
Halozyme
HALO
$9.14B
| $8.89M | 4.25% |
+240,448
| New | +$9.06M |
|
13
Perrigo
PRGO
$1.47B
| $8.37M | 4% |
+260,000
| New | +$7.77M |
|
14
Pfizer
PFE
$141B
| $7.63M | 3.65% |
+265,000
| New | +$8.01M |
|
15
Bristol-Myers Squibb
BMY
$123B
| $7.18M | 3.43% |
+140,000
| New | +$7.35M |
|
16
CRISPR Therapeutics
CRSP
$4.63B
| $6.73M | 3.22% |
+107,500
| New | +$5.94M |
|
17
Viridian Therapeutics
VRDN
$2.05B
| $6.7M | 3.2% |
+307,721
| New | +$4.86M |
|
|
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
| $6.46M | 3.09% |
+108,000
| New | +$5.48M |
|
19
Iovance Biotherapeutics
IOVA
$2.24B
| $5.51M | 2.63% |
+677,350
| New | +$3.54M |
|
20
Cabaletta Bio
CABA
$448M
| $5.22M | 2.5% |
+230,000
| New | +$3.87M |
|
21
Prestige Consumer Healthcare
PBH
$2.39B
| $5.2M | 2.49% |
+85,000
| New | +$5.05M |
|
22
BridgeBio Pharma
BBIO
$15.8B
| $4.17M | 1.99% |
+103,324
| New | +$3.1M |
|
23
Arcus Biosciences
RCUS
$3.54B
| $3.68M | 1.76% |
+192,667
| New | +$3.08M |
|
Similar funds
SAM
CW
IAM
BCM
CWM
RI
LA
GWA
Cutter Capital Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Cutter Capital Management, which disclosed 23 positions worth $209M. Its ten largest holdings account for 59% of the portfolio.
Its largest position is Amgen: 57,381 shares worth $16.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Cutter Capital Management's largest Q4 2023 buy was Amgen: 57,381 shares worth $16.5M.
- Cutter Capital Management's ten largest holdings make up 59% of its $209M portfolio in Q4 2023.
- Cutter Capital Management disclosed 23 positions in Q4 2023, its first 13F filing on record.
Based on Cutter Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.